Chemokine receptors: attractive targets for drug discovery.
Studies of two antibodies, efalizumab and natalizumab, have recently demonstrated that the blockade of leukocyte migration is of therapeutic benefit for the treatment of diseases such as psoriasis and multiple sclerosis. The role of chemokines in the control of cell traffic led to their receptors being considered one of the most promising family of targets aimed at disrupting cell recruitment in chronic inflammatory processes. Choosing the appropriate chemokine receptor for each disease was not easy, and the interpretation of target validation studies proved to be extremely difficult. Despite an intense effort in the search for chemokine receptor antagonists in the last decade, no compounds in advanced clinical trials exist as such. The inherent complexity of the family, the differences between the chemokine system in mice and men, and the species selectivity of small-molecule compounds could account for this fact. Pharmaceutical companies still believe in chemokine receptors as therapeutic targets, as demonstrated by the number of compounds reported to be in development. In the next years, the developmental progression of these compounds will reveal which target within the chemokine family is of real therapeutic value.
Godessart
Nuria
N
Department of Biology, Almirall Research Center, Cardener 68-74, 08024 Barcelona, Spain. ngodessa@almirall.es
D000818:Animals; D002465:Cell Movement; D018925:Chemokines / Q000737:chemistry / Q000145:classification / Q000502:physiology; D015195:Drug Design; D006801:Humans; D051379:Mice; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*
D018925:Chemokines; D019707:Receptors, Chemokine